A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

European Journal of Cancer

Volumn 50, Issue 12, 2014, Pages 2072-2081

  Infante, Jeffrey R ^a   Somer, Bradley G ^b   Park, Joon Oh ^c   Li, Chung Pin ^d,e   Scheulen, Max E ^f   Kasubhai, Saifuddin M ^g   Oh, Do Youn ^h   Liu, Yuan ⁱ   Redhu, Suman ⁱ   Steplewski, Klaudia ⁱ   Le, Ngocdiep ^j  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b West Clinic   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g Pac International Engineering PLLC   (United States)

^h Seoul National University Hospital   (South Korea)

ⁱ GLAXOSMITHKLINE   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Gemcitabine; MEK inhibitor; Pancreas; Randomised; Trametinib

Indexed keywords

COMPLEMENTARY DNA; GEMCITABINE; K RAS PROTEIN; PLACEBO; RAS PROTEIN; TRAMETINIB;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEART DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC PANCREAS ADENOCARCINOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

GEMCITABINE; MEK INHIBITOR; PANCREAS; RANDOMISED; TRAMETINIB;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; SURVIVAL ANALYSIS;

EID: 84904063663     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.024     Document Type: Article

References (22)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 1 2013 11 30
2. H.A. Burris, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403 2413
3. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group J Clin Oncol 25 15 2007 1960 1966
4. S.R. Bramhall, J. Schulz, J. Nemunaitis, P.D. Brown, M. Baillet, and J.A. Buckels A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2 2002 161 167
5. E. Van Cutsem, H. van de Velde, P. Karasek, H. Oettle, W.L. Vervenne, and A. Szawlowski et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 8 2004 1430 1438
6. J. Tabernero, and T. Macarulla Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development J Clin Oncol 27 33 2009 5487 5491
7. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, and Y. Becouarn et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 19 2011 1817 1825
8. D.D. Von Hoff, T.J. Ervin, F.P. Arena, E.G. Chiorean, J.R. Infante, and M.J. Moore et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT) J Clin Oncol 31 4-Suppl. 2013 LBA48
9. P.J. Roberts, and C.J. Der Targeting the raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 22 2007 3291 3310
10. J.S. Sebolt-Leopold Development of anticancer drugs targeting the MAP kinase pathway Oncogene 19 56 2000 6594 6599
11. C. Fremin, and S. Meloche From basic research to clinical development of MEK1/2 inhibitors for cancer therapy J Hematol Oncol 3 2010 8
12. A.G. Gilmartin, M.R. Bleam, A. Groy, K.G. Moss, E.A. Minthorn, and S.G. Kulkarni et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin Cancer Res 17 5 2011 989 1000
13. J.R. Infante, L.A. Fecher, G.S. Falchook, S. Nallapareddy, M.S. Gordon, and C. Becerra et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 13 8 2012 773 781
14. A.W. Tolcher, J.C. Bendell, A. Patnaik, K. Papadopoulos, K.M. Bellew, and D.S. Cox et al. A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: interim results J Clin Oncol 29 4-Suppl. 2011 278
15. Declaration of helsinki - ethical principles for medical research involving human subjects [homepage on the Internet]. Available from: < http://www.wma.net/en/30publications/10policies/b3/ >; 2012.
16. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
17. Common terminology criteria for adverse events (CTCAE) v4.03.[homepage on the Internet]. Available from: < http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4. 03-2010-06-14-QuickReference-8.5x11.pdf >; 2010.
18. F. Diehl, K. Schmidt, M.A. Choti, K. Romans, S. Goodman, and M. Li et al. Circulating mutant DNA to assess tumor dynamics Nat Med 14 9 2008 985 990
19. J.R. Infante, K.P. Papadopoulos, J.C. Bendell, A. Patnaik, H.A. Burris 3rd, and D. Rasco et al. A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours Eur J Cancer 49 9 2013 2077 2085
20. A. Santiago-Walker, B. Gagnon, J. Mazumdar, M. Casey, P. Haney, and A. O'Hagan et al. Correlation of BRAF mutation status in cfDNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials Pigment Cell Melanoma Res 26 6 2013 997
21. J. Xu, J.J. Knox, E. Ibrahimov, E. Chen, S. Serra, and M. Tsao et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer Clin Cancer Res 19 1 2013 118 127
22. P.A. Janne, A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, and C. Barrios et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 1 2013 38 47